CLINICAL TRIAL

Treatment for Plasma Cell Myeloma

Recruiting · 18+ · All Sexes · Rochester, MN

This study is evaluating whether glutamine may be used differently by the bone marrow in multiple myeloma and monoclonal gammopathy of undetermined significance.

See full description

About the trial for Plasma Cell Myeloma

Eligible Conditions
Plasma Cell Myeloma · Neoplasms, Plasma Cell · Monoclonal Gammopathy of Unknown Significance · Multiple Myeloma

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received newly diagnosed for Plasma Cell Myeloma or one of the other 3 conditions listed above. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
IMWG criteria for the diagnosis of either MGUS or MM5
Presence of measurable disease defined by an M-spike of >1 g/dL and/or involved serum free immunoglobulin light chain >10 mg/dL
At least 5 to <10% cPCs in the prior BM aspirate
Not received any plasma cell directed therapy
For MM cohort
At least >10% cPCs in recent BM aspirate
Newly diagnosed MM without receiving any plasma cell directed therapy OR Relapsed MM without having received salvage chemotherapy
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 day
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 day.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Plasma Cell Myeloma. Measurement will happen over the course of 1 day.

Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma from patients with MGUS and Multiple Myeloma.
1 DAY
Compare the glutamine anaplerosis activity in the plasma cells by assessing the bone marrow plasma between patients with MGUS and Multiple Myeloma.
Percent enrichment of 13-Carbon in the TCA cycle intermediates within the peripheral blood plasma from patients with MGUS and Multiple Myeloma.
1 DAY
Compare the peripheral blood enrichment of 13-carbon in the TCA cycle intermediates from patients with MGUS and Multiple Myeloma.
Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma cells from patients with MGUS and Multiple Myeloma.
1 DAY
Compare the glutamine anaplerosis activity in bone marrow clonal plasma cells between patients with MGUS and Multiple Myeloma.

Who is running the study

Principal Investigator
W. I. G. M.
Wilson I. Gonsalves M.D., Senior Associate Consultant
Mayo Clinic

Patient Q & A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Plasma Cell Myeloma by sharing your contact details with the study coordinator.